As all Vioxx users have been aware over the last year of so there has been a class action suit against the makers of Vioxx because of the inadequate testing or reporting of risks associated with Vioxx. Well the case has not concluded with almost 5 Billion dollars going to those that have suffered from the arthritis pain killer drug.

Merck & Co. said Friday it will pay $4.85 billion to end thousands of lawsuits over its painkiller Vioxx in what is believed to be the largest drug settlement ever.

The deal becomes binding only if 85 percent of all plaintiffs in about 26,600 lawsuits agree to drop their cases. It was finalized in the early morning hours after attorneys for Merck and the plaintiffs met with three of the four judges overseeing nearly all Vioxx claims.

Merck faced personal injury lawsuits representing 47,000 plaintiffs, and about 265 potential class action cases, filed by people or family members who claimed the drug proved fatal or injured its users. The agreement covers cases filed in both federal and state courts.

Negotiating teams met more than 50 times in eight states and spoke hundreds of times over the telephone to hammer out the deal, according to attorneys.

“I’m very happy with it,” Chris Seeger, one of the six plaintiff lawyers who helped negotiate the settlement, said Friday. “It’s a tremendous way to resolve this litigation.”

Merck pulled Vioxx from the market Sept. 30, 2004 after its own research determined the then-blockbuster painkiller doubled risk of heart attacks and strokes.

Seeger said the deal was put in motion last December when three key judges pushed the parties to open out-of-court talks.

“Every claimant is going to be compensated” once their claim is validated, he said.

Seeger believes it is the largest settlement ever in the industry and said he will recommend that his 2,000 clients accept the deal.

Merck could put the uncertainty of millions of dollars in possible settlements that have plagued the pharmaceutical company behind it, though it has been fairly successful fighting cases individually, winning 10 of 15 court verdicts to date.

Looking to make a change and lose some weight? I have reviewed the top diet on the internet and you can go and read over 200 comments people have made about why this diet has worked well for them, as well as some of the problems.

Tags: arthritis, Chris Seeger, heart attacks, Merck, Merck & Co., pain, pharmaceutical, testing, USD, vioxx

Two years ago there were problems found with arthritis medications that contained Cox-2 inhibitors and both Vioxx and Celebrex were pulled off of the market. If you remember the problem was that users of these products had a higher inciednce of cariac problems compared to a control group that took a placebo. Now Merck, one of the largest drug manufacturers worldwide is trying to create a new drug called Arcoxia that also uses Cox-2 inhibitors as a painkiller to tackle arthritis pain.

Merck wants FDA approval to sell Arcoxia, also known as etoricoxib, to treat the signs and symptoms of osteoarthritis. The Whitehouse Station, N.J. company said its drug should be an option for the estimated 21 million Americans who suffer from osteoarthritis.

The FDA is at this point against this new drug although Merck says that the results are the same as an older Arthritis drug called Diclofenac which although older is apparently safe.

The reason that I bring this all up today is because it seems that after the initial hype and banning of Cox-2 based pain control there have not been many studies and it would be nice to see more info on the good or the bad of these Cox-2 based drugs

Tags: Arcoxia, arthritis, control group, Cox, Diclofenac, fda, Merck, New Jersey, osteoarthritis, pain, vioxx, Whitehouse Station

A huge review of studies on pain relievers has found that a widely-used medicine may confer cardiovascular risks as serious as those found with Vioxx, an arthritis medicine that was withdrawn from the market two years ago.

Diclofenac, marketedas Voltaren, Cataflam, Solaraze and Arthrotec, an older non-steroidal anti-inflammatory drug (NSAID), has been on the market for decades and is one of the most-widely prescribed anti-inflammatories in the world especially in Europe. At commonly prescribed doses, it was found to increase the risk of cardiovascular events primarily heart attack and sudden death by 40%.

The good news from the study is that there are alternatives. “European consumers would be better off switching [from diclofenac] to naproxen,” says David Graham, a safety official at the US Food and Drug Administration, who authored an editorial1 accompanying the published review. Naproxen was found to neither increase nor decrease cardiac risk.
Read the rest of this entry »

Tags: American Medical Association, arthritis, atherosclerosis, Australia, David Graham, David Henry, Europe, heart attack, heart disease, New South Wales, Newcastle Mater Hospital, pain, Patricia McGettigan, safety official, the Journal of the American Medical Association, University of Newcastle in New South Wales, US Food and Drug Administration, vioxx, Waratah

Perhaps Vioxx and Celebrex and the Cox-2 inhibitors are not the culprit. There is an important report from England that is saying that using Ibuprofen as an arthritis pain killer will raise your heart attack risk as much as Vioxx or Celebrex.

High doses of older painkiller drugs may pose the same cardiac risk as newer medications such as
Vioxx and other cox-2 inhibitor drugs, according to a British study that looked at what is regarded as the best evidence from randomized, controlled trials.

Data from 138 such trials with 140,000 participants showed a 42 percent increased risk of serious blood vessel problems such as heart attack and stroke in those taking selective cox-2 inhibitors, the chemical class that includes Vioxx ,
Bextra and Celebrex. Cox-2 inhibitors belong to a broader class of pain relievers called nonsteroidal anti-inflammatory drugs (NSAIDs), which also include non-cox-2 medications such as ibuprofen, diclofenac, naproxen and aspirin.

And the study — which was funded by various U.K. public-sector medical groups — also found a similar increase in cardiac risk for other NSAIDs, said Dr. Colin Baigent, a reader in clinical epidemiology at the University of Oxford and an author of the report in the June 3 issue of the British Medical Journal.

Specifically, long-term use of high-dose (800 milligrams three times per day) ibuprofen was associated with a 51 percent higher risk for “vascular events” compared to placebo, while long-term use of high-dose (75 milligrams two times a day) diclofenac boosted the risk by 63 percent, the U.K. team reported. No such risk was seen with long-term use of naproxen (sold under the brand name Aleve).
Read the rest of this entry »

Tags: Aleve, arthritis, Author, Cataflam, chemical class, Cleveland Clinic, Colin Baigent, Cox, heart attack, heart disease, ibuprofen, interim chairman, Massage, Merck, Merck & Co., Motrin, pain, pain killing products, Steven Nissen, the British Medical Journal, United Kingdom, University of Oxford, vioxx

The blockbuster drug Vioxx was pulled from the market in the fall of 2004 after research showed that the painkiller doubled the risk of heart attack and stroke and that its use may have contributed to thousands of deaths in North America.
Now, a new Canadian study shows that the risk was even more dramatic because one in four of the heart attacks that occurred were within two weeks of the start of treatment.
“This demonstrates that cardiovascular risks from taking Vioxx may occur much earlier than previously believed,” said Linda Lévesque, an assistant professor in the department of community health and epidemiology at Queen’s University in Kingston.
At the same time, however, the research shows that additional risk virtually disappears within a month, meaning it is likely safe for long-term use.
The earlier data had suggested that the risk remained elevated for up to 18 months.
The research was published yesterday in the on-line edition of the Canadian Medical Association Journal.
Read the rest of this entry »

Tags: assistant professor in the department, Canada, Celebrex, Cox, digestive chemicals, director of the institute, heart attack, heart attacks, ibuprofen, Kingston, McGill University, Merck & Co. Inc., north America, on-line edition, Peter Liu, Quebec, Queen's University in Kingston, scientific director, stroke, the Canadian Medical Association Journal, United States, vioxx

My wife at 32 has arthritis in her back and over the years has done almost everything to get rid of the pain. Michelle thinks that the arthritis stems from a car accident sh was in when she was a kid and never had it heal properly, but the pain is still there. These are the things Michelle has done over the years to get rid of the pain:

Lose Weight to ease back pain – this has helped her health overall and you would expect it to stop the back pain but it has not.

Massage to help back pain – Michelle had massage on and off for about two years and although it helped her feel better overall it did not seem to help her back very much.

Exercise to improve back problems – both cardio and weight lifting have been a part of Michelles life for years, over time the pain has come and gone and then come back but the exercise has definitely helped some.
Read the rest of this entry »

Tags: arthritis, back pain, car accident, Celebrex, Massage, pain, pain in her back, vioxx